Last reviewed · How we verify
pegaptanib sodium injection
pegaptanib sodium injection is a VEGF inhibitor (aptamer) Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Neovascular (wet) age-related macular degeneration. Also known as: Macugen.
Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration.
At a glance
| Generic name | pegaptanib sodium injection |
|---|---|
| Also known as | Macugen |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | VEGF inhibitor (aptamer) |
| Target | VEGF165 (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Pegaptanib is a pegylated RNA aptamer that specifically targets VEGF165, the predominant isoform involved in pathological neovascularization. By blocking VEGF signaling, it reduces vascular permeability and inhibits the formation of new abnormal blood vessels in age-related macular degeneration, thereby slowing vision loss.
Approved indications
- Neovascular (wet) age-related macular degeneration
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Anterior chamber inflammation
- Cataracts
- Endophthalmitis
Key clinical trials
- Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema (NA)
- Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium (PHASE4)
- A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. (PHASE2, PHASE3)
- Cohort Study of the Clinical Course of Macular Diseases in Kagawa (PHASE4)
- Cohort Study of the Clinical Course of Macular Diseases in Japanese
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib (PHASE3)
- Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pegaptanib sodium injection CI brief — competitive landscape report
- pegaptanib sodium injection updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about pegaptanib sodium injection
What is pegaptanib sodium injection?
How does pegaptanib sodium injection work?
What is pegaptanib sodium injection used for?
Who makes pegaptanib sodium injection?
Is pegaptanib sodium injection also known as anything else?
What drug class is pegaptanib sodium injection in?
What development phase is pegaptanib sodium injection in?
What are the side effects of pegaptanib sodium injection?
What does pegaptanib sodium injection target?
Related
- Drug class: All VEGF inhibitor (aptamer) drugs
- Target: All drugs targeting VEGF165 (vascular endothelial growth factor)
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Neovascular (wet) age-related macular degeneration
- Also known as: Macugen
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing